Patients receiving anti PD-1/anti-CTLA-4 combination therapy were younger (p = 0.043) and exclusively treated for melanoma (p = 0.003), when compared to patients receiving anti PD-1 monotherapy. The gene discussed is CTLA4; the disease is melanoma.